Catalent, Inc. (NYSE:CTLT) Shares Sold by KBC Group NV

KBC Group NV lessened its holdings in Catalent, Inc. (NYSE:CTLTFree Report) by 33.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,249 shares of the company’s stock after selling 17,449 shares during the quarter. KBC Group NV’s holdings in Catalent were worth $1,539,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of CTLT. Vanguard Group Inc. boosted its position in Catalent by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after purchasing an additional 365,648 shares in the last quarter. Cadian Capital Management LP boosted its position in Catalent by 91.0% in the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock worth $241,527,000 after purchasing an additional 2,526,750 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Catalent by 65.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock worth $158,601,000 after purchasing an additional 1,384,313 shares in the last quarter. Norges Bank purchased a new stake in Catalent in the 4th quarter worth approximately $116,021,000. Finally, Northern Trust Corp boosted its position in Catalent by 13.6% in the 3rd quarter. Northern Trust Corp now owns 2,160,603 shares of the company’s stock worth $98,372,000 after purchasing an additional 258,482 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on CTLT shares. StockNews.com started coverage on Catalent in a research report on Thursday. They issued a “sell” rating on the stock. Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Catalent currently has a consensus rating of “Hold” and a consensus price target of $53.14.

Get Our Latest Research Report on Catalent

Catalent Trading Up 0.3 %

Shares of CTLT stock opened at $56.39 on Friday. The stock’s fifty day moving average is $55.74 and its two-hundred day moving average is $51.99. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The firm has a market capitalization of $10.21 billion, a P/E ratio of -9.24, a PEG ratio of 5.80 and a beta of 1.20. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLTGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Research analysts expect that Catalent, Inc. will post 0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

(Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Articles

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.